Picture loading failed.

Anti-IGHE therapeutic antibody (Pre-made Ligelizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ligelizumab (INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. It is an anti-IgE that binds to IGHE an acts as an immunomodulator.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-312-1mg 1mg 3090
GMP-Bios-ab-312-10mg 10mg 21890
GMP-Bios-ab-312-100mg 100mg 148000
GMP-Bios-ab-312-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IGHE therapeutic antibody (Pre-made Ligelizumab biosimilar,Whole mAb)
INN Name Ligelizumab
TargetIGHE
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusActive
100% SI Structure6uqr:AC
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2012
Year Recommended2013
CompaniesNovartis;Tanox
Conditions Approvedna
Conditions ActiveUrticaria;Allergic asthma;Atopic dermatitis;Bullous pemphigoid
Conditions DiscontinuedHypersensitivity
Development Techna